Tenecteplase fibrinolysis

Description Results NMA

Short-term death 1.58 [1.02; 2.43]

Short-term non-fatal reinfarction 1.82 [1.12; 2.97]

Short-term urgent target vessel revascularisation 4.56 [2.13; 9.75]

Initial TIMI 3 flow 2.90 [2.42; 3.46]

Short-term major bleeding in patients treated 1.26 [0.82; 1.92]

Final TIMI 3 flow 0.99 [0.95; 1.02]

Initial TIMI 3 flow 4.90 [2.90; 8.28]

Short-term death 0.62 [0.15; 2.54]

Short-term major bleeding in patients treated 0.35 [0.04; 3.27]

Short-term non-fatal reinfarction 1.04 [0.07; 16.39]

Short-term urgent target vessel revascularisation 1.04 [0.07; 16.39]

Final TIMI 3 flow 1.04 [0.92; 1.16]

facilated PCI with tenecplase bodyweight-adjusted intravenous bolus: 30 mg of drug if bodyweight <60 kg, 35 mg if60–69 kg, 40 mg if 70–79 kg, 45 mg if 80–89 kg, and 50 mg if >=90 kg (n=829)

vs.

primary intervention (n=838)

Sample size: 829/838

Primary endpoint:

FU duration: 30-day

facilated PCI with bodyweight-adjusted intravenous tenecteplase bolus: 30 mg of drug if bodyweight <60 kg, 35 mg if60–69 kg, 40 mg if 70–79 kg, 45 mg if 80–89 kg, and 50 mg if >=90 kg and Abciximab; 0·25 mg/kg intravenousbolus, 0·125 g/kg per min infusi (n=104)

vs.

primary intervention (n=108)

Sample size: 104/108

Primary endpoint:

FU duration: 30-day

facilated PCI with Eptifibatide, 180 µg/kg intravenous double bolus, 2·0 µg/kg per min infusion and tenecteplase 0·25 mg/kg (intravenous bolus) (n=69)

vs.

(n=77)

Sample size: 69/77

Primary endpoint:

FU duration: 30 days

Hémorragies majeures précoces 0.78 [0.69; 0.89]

Mortalité précoce 1.01 [0.89; 1.13]

AVC précoce 1.07 [0.86; 1.35]

Tenecteplase en IV bolus (dose en fonction du poids: 30 mg si < 60 kg; 35 mg si poids entre 60 et 69.9 kg; 40 mg pour les 80-89.9 kg; 50 mg si > ou = 90 kg (n=8461)

vs.

Alteplase en IV, bolus de 15 mg, puis 0.75 mg/kg (sans dépasser 50 mg) en 30 min puis 0.50 mg/kg (sans dépasser 35 mg) en 60 min (n=8488)

double blind

Parallel groups

Sample size: 8461/8488

Primary endpoint: Mortality 30-day

FU duration: 30d

death 0.87 [0.66; 1.14]

Ischemic stroke 0.87 [0.66; 1.14]

Symptomatic intracranial hemorrhage 0.87 [0.66; 1.14]

Survival to hospital discharge 0.87 [0.66; 1.14]

Return of spontaneous circulation 0.87 [0.66; 1.14]

failure to return of spontaneous circulation 1.03 [0.97; 1.08]

death before hospital discharge 1.03 [0.97; 1.08]

death 0.95 [0.78; 1.17]

tenecteplase (dose according to estimated body weight) (n=525)

vs.

placebo (n=525)

doubel blind

Parallel groups

Sample size: 525/525

Primary endpoint: 30-day survival

FU duration: 30 days

tenecteplase 50 mg (n=19)

vs.

placebo (n=16)

double blind

Parallel groups

Sample size: 19/16

Primary endpoint: return of spontaneous circulation

FU duration: